Layman's heaven

Found on the wall of an office:

'Sullivan's law: Murphy was an optimist'

In layman's dreams SimplyWall St's estimates were pessimistic.

Layman's dreams consist projects as a whole sold by Faron and new phase II projects including transfers.  The development of next ones are based on deep studies of their own and effective radars.

Bexmarilimab "Faron’s current priority is its Phase I/II BEXMAB trial, investigating the safety, tolerability and preliminary efficacy of bexmarilimab in combination with standard of care therapies, azacitidine and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes (MDS) and relapsed/refractory acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML)."

Traumakine "is investigational intravenous (IV) interferon beta-1a (IFN beta-1a) therapy for the prevention of complications from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions... It offers a potential therapeutic for emergency and trauma patients." Immunotherapies, including Bex itself, and viruses may cause excessive cytokine releases and SARS may cause its fatal mode, cytokine storm. (Treatment against SARS?) ('Long covid' IS a cytokine release syndrome, but authorities don't understand or confess the connection to vaccines)

Layman's heaven: 

No1 as a whole: Bexmarilimab/ hematological malignancies sold for 12-15 mrd€

No2 as a whole: Traumakine sold for 5-8 mrd€

Pipelines:

a. Bexmarilimab/ solid tumors- single ones and groups?

"A broad development program is underway" "In solid tumors, the result is increased antigen presentation, secretion of proinflammatory cytokines such as IFN-gamma (which is critical for both innate and adaptive immunity), and activation of T cells, converting nonresponsive ‘cold’ tumors into responsive ‘hot’ tumors." 

b. soluble Clever-1

c. ...

etc.  

But Christmas is certain, Peaceful Xmas but a happy New Year!